External Advisory Board

Richard DiMarchi, Ph.D.
Richard DiMarchi, Ph.D., chair

Dr. DiMarchi is the Standiford H. Cox Distinguished Professor of Chemistry and the Linda and Jack Gill Chair in Biomolecular Sciences at Indiana University. He has more than 25 years of pharmaceutical industry experience, including serving as vice president of endocrine research and group vice president of biotechnology at Eli Lilly and Company. He is the founder of four biotech startups and serves on the board of multiple companies.

Jamie Dananberg, M.D.
Jamie Dananberg, M.D.

Dr. Dananberg is head of the cardiovascular and metabolic therapeutic area unit at Takeda Pharmaceuticals. He has extensive pharmaceutical industry experience. He is also an active member of the Indiana Clinical and Translational Sciences Institute.

John D. Diekman, Ph.D.
John D. Diekman, Ph.D.

Dr. Diekman is founder and managing partner of 5AM Ventures. He currently serves as board chairman of Ambrx and Envoy Therapeutics. He is a member of the boards of Igenica, Ingenuity Systems, Marcadia Biotech, PhaseRx, and Wildcat Discovery.

Ron Laufer, M.D.
Ron Laufer, M.D.

Dr. Laufer is senior managing director of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. He co-founded Lilly Ventures, the venture capital arm of Eli Lilly and Company, and was a managing director at Visium Asset Management, a private health care-focused investment firm.

Alan Palkowitz, Ph.D.
Alan Palkowitz, Ph.D.

Dr. Palkowitz is vice president of discovery chemistry research and technologies at Lilly Research Laboratories. He created Lilly’s Open Innovation Drug Discovery (OIDD) platform, a drug-development initiative that allows external researchers to use Lilly science to find compounds that have potential to become new medicines.

Franklyn G. Prendergast, Ph.D.

Dr. Prendergast is director of the Mayo Clinic Center for Individualized Medicine as well as the Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology at the Mayo Clinic. He serves on the boards of numerous companies and organizations, including Eli Lilly and Company, the Translational Genomics Research Institute, and the Infectious Disease Research Institute. He is a member of the NCAT council.

Darryle D. Schoepp, Ph.D.
Darryle D. Schoepp, Ph.D.

Dr. Schoepp is senior vice president and franchise head for neuroscience and ophthalmology at Merck Research Laboratories. He was in neuroscience discovery research at Eli Lilly and Company, where he served as vice president and overall global head of neuroscience research and early clinical investigation.

Brian Sweet
Brian Sweet

Brian Sweet is executive director of U.S. Payer & Real World Evidence at AstraZeneca. He focuses on initiatives in real-world evidence (RWE) and comparative effectiveness research.

Nancy Thornberry
Daria Mochly-Rosen, Ph. D.

Dr. Daria Mochly-Rosen is the George D. Smith Professor of Translational Medicine and Professor at the Department of Chemical and Systems Biology at Stanford University. She is the founder and director of the SPARK program at Stanford.